See every side of every news story
Published loading...Updated

Expanded access program in MS for nasal foralumab doses 4 more

Summary by Multiple Sclerosis News Today
Four more people with nonactive secondary progressive multiple sclerosis (SPMS) have received foralumab nasal spray — Tiziana Life Sciences’ therapy candidate for SPMS — via an expanded access program, the biotechnology company announced. That program allows patients who do not qualify for an ongoing Phase 2a clinical trial (NCT06292923) to still have access to the […] The post Expanded access program doses 4 new patients with nasal foralumab ap…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Multiple Sclerosis News Today broke the news in on Thursday, February 20, 2025.
Sources are mostly out of (0)